CL2014000269A1 - Uso de interleucina 7 (il-7) para tratar hepatitis c en combinacion o con posterioridad a un agente antiviral o una combinacion de agentes antivirales. - Google Patents

Uso de interleucina 7 (il-7) para tratar hepatitis c en combinacion o con posterioridad a un agente antiviral o una combinacion de agentes antivirales.

Info

Publication number
CL2014000269A1
CL2014000269A1 CL2014000269A CL2014000269A CL2014000269A1 CL 2014000269 A1 CL2014000269 A1 CL 2014000269A1 CL 2014000269 A CL2014000269 A CL 2014000269A CL 2014000269 A CL2014000269 A CL 2014000269A CL 2014000269 A1 CL2014000269 A1 CL 2014000269A1
Authority
CL
Chile
Prior art keywords
combination
antiviral
interleukin
treat hepatitis
antiviral agent
Prior art date
Application number
CL2014000269A
Other languages
English (en)
Inventor
Michel Morre
Brigitte Assoulne
Therese Croughs
Pierre Demol
Stephanie Beq
Original Assignee
Cytheris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628658&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000269(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytheris filed Critical Cytheris
Publication of CL2014000269A1 publication Critical patent/CL2014000269A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2014000269A 2011-08-03 2014-02-03 Uso de interleucina 7 (il-7) para tratar hepatitis c en combinacion o con posterioridad a un agente antiviral o una combinacion de agentes antivirales. CL2014000269A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306012 2011-08-03
US201161514915P 2011-08-04 2011-08-04

Publications (1)

Publication Number Publication Date
CL2014000269A1 true CL2014000269A1 (es) 2014-10-10

Family

ID=47628658

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000269A CL2014000269A1 (es) 2011-08-03 2014-02-03 Uso de interleucina 7 (il-7) para tratar hepatitis c en combinacion o con posterioridad a un agente antiviral o una combinacion de agentes antivirales.

Country Status (18)

Country Link
US (1) US20140377218A1 (es)
EP (1) EP2739301B1 (es)
JP (1) JP2014521679A (es)
KR (1) KR20140063657A (es)
CN (1) CN103917240A (es)
AU (1) AU2012292032A1 (es)
BR (1) BR112014002365A2 (es)
CA (1) CA2843495A1 (es)
CL (1) CL2014000269A1 (es)
CR (1) CR20140101A (es)
EA (1) EA201490399A1 (es)
ES (1) ES2568755T3 (es)
HK (1) HK1202794A1 (es)
IL (1) IL230669A0 (es)
MX (1) MX2014001355A (es)
SG (1) SG10201606395XA (es)
WO (1) WO2013017653A1 (es)
ZA (1) ZA201401986B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2708160C2 (ru) * 2015-06-11 2019-12-04 Дженексин, Инк. Модифицированный белок интерлейкина-7 и способы его применения
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
KR102604595B1 (ko) 2015-12-04 2023-11-21 주식회사 제넥신 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 인플루엔자 바이러스 감염의 예방 또는 치료용 약학적 조성물
WO2017095191A1 (ko) 2015-12-04 2017-06-08 주식회사 제넥신 면역글로불린 fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물
WO2017176672A1 (en) * 2016-04-04 2017-10-12 The Regents Of The University Of California Compositions and methods related to polycytotoxic t cells
JP2022547056A (ja) * 2019-09-04 2022-11-10 ジェネクシン・インコーポレイテッド 腫瘍においてｉｌ－７融合タンパク質を用いてリンパ球数を増加させる方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
ZA887773B (en) 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
ATE181557T1 (de) 1993-02-24 1999-07-15 Jui H Wang Zusammensetzungen und methoden zur anwendung von reaktiven antiviralen polymeren
CA2167537A1 (en) 1993-07-19 1995-02-02 Tsuneo Ozeki Hepatitis c virus proliferation inhibitor
DE4432623A1 (de) 1994-09-14 1996-03-21 Huels Chemische Werke Ag Verfahren zur Bleichung von wäßrigen Tensidlösungen
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
GEP20032995B (en) 1997-06-30 2003-06-25 Merz & Co Gmbh & Co 1-Amino-Alkylcyclohexane NMDA Receptor Antagonists
EP1391513A1 (en) 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
DE602004013372T2 (de) 2003-12-30 2009-07-02 Merck Patent Gmbh Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
CN101152567A (zh) * 2006-09-29 2008-04-02 上海新生源医药研究有限公司 重组人白介素-11的药物组合
CN102665753A (zh) 2009-07-31 2012-09-12 佛多斯大学医学研究中心 诊断或预测hcv感染的患者中丙型肝炎后果的方法

Also Published As

Publication number Publication date
HK1202794A1 (zh) 2015-10-09
BR112014002365A2 (pt) 2017-02-21
SG10201606395XA (en) 2016-09-29
EP2739301A1 (en) 2014-06-11
AU2012292032A1 (en) 2014-03-13
MX2014001355A (es) 2014-11-21
CR20140101A (es) 2014-05-26
ZA201401986B (en) 2015-07-29
CA2843495A1 (en) 2013-02-07
EA201490399A1 (ru) 2014-06-30
IL230669A0 (en) 2014-03-31
ES2568755T3 (es) 2016-05-04
CN103917240A (zh) 2014-07-09
JP2014521679A (ja) 2014-08-28
WO2013017653A1 (en) 2013-02-07
US20140377218A1 (en) 2014-12-25
KR20140063657A (ko) 2014-05-27
EP2739301B1 (en) 2016-01-20
NZ620689A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
CL2014001291A1 (es) Agentes de iarn de doble hebra; composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr).
CO6831975A2 (es) Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
HK1216420A1 (zh) -元雜芳及其用作抗病毒劑
SMT201500148B (it) Composizioni per uso nel trattamento di infezioni virali
CL2014000269A1 (es) Uso de interleucina 7 (il-7) para tratar hepatitis c en combinacion o con posterioridad a un agente antiviral o una combinacion de agentes antivirales.
SI3071696T1 (sl) C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
BR112014009634A2 (pt) preparação e agente terapêutico
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
TR201902516T4 (tr) Glukagon-glp-1-gıp üçlü agonist bileşikleri.
CL2008000188A1 (es) Agente para suprimir la reaccion de rechazo cronica que comprende como ingrediente activo un inhibidor de il-6; y uso del inhibidor de il-6.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
IT1403661B1 (it) Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
BR112013023681A2 (pt) compostos de álcool propargílico 6,5-heterocíclico e uso dos mesmos
PL2961819T3 (pl) Wodne preparaty, ich wytwarzanie i ich zastosowanie do czyszczenia twardych powierzchni
PL2768937T3 (pl) Preparaty, ich zastosowanie jako środków do mycia naczyń lub do wytwarzania środków do mycia naczyń i ich wytwarzanie
CL2015000499A1 (es) Uso de un agente farmacéuticamente aceptable que elimina el antígeno de superficie de la hepatitis b de la sangre y un segundo agente que estimula la función inmunitaria, para tratar hepatitis b o coinfección hepatitis b/hepatitis d; y composición que comprende ambos agentes.
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
BR112014009949A8 (pt) métodos de tratamento de hipersecreção de muco e uso de agentes
BR112014010739A2 (pt) agentes terapêuticos e uso dos mesmos
CL2013001324A1 (es) Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.
CL2014000671A1 (es) Composicion farmaceutica que comprende rifabutina, claritromicina y clofazimina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple y sus sintomas asociados, tiroiditis de hashimoto y sindrome de melkersson o sarcoidosis.
CO6700840A2 (es) Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia
BR112014000773A2 (pt) composições de nicotinamida e uso terapêutico das mesmas
CL2014002221A1 (es) Composiciones y métodos para aplicar de manera precisa un agente bioactivo a organismos acuáticos.